Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the development of next-generation radioligand medicines.

赛诺菲（Sanofi）和Orano集团的子公司Orano Med（肿瘤靶向α疗法开发的先驱）已达成协议，将他们在抗击罕见癌症方面的专业知识结合起来，并进一步加速下一代放射性配体药物的开发。

Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will invest in a new entity, operating under the Orano Med brand, and focusing on the discovery, design, and clinical development of next-generation radioligand therapies (RLTs) based on lead-212 (212Pb) alpha-emitting isotopes.

基于Orano Med的专业知识和放射性配体管道，赛诺菲和Orano将投资一家新实体，以Orano Med品牌运营，专注于基于铅212（212Pb）α发射同位素的下一代放射性配体疗法（RLT）的发现，设计和临床开发。

This agreement follows Sanofi’s announcement of an exclusive licensing agreement with Orano Med and RadioMedix to advance radioligand therapies (RLTs) in rare cancers with a focus on one late-stage project, AlphaMedix™. Targeted alpha therapy relies on a simple concept: combining the ability of biological vectors to target cancer cells with the short-range and highly energetic cell-killing capabilities of alpha-emitting radioisotopes.

赛诺菲宣布与Orano Med和RadioMedix签订独家许可协议，以推进罕见癌症的放射性配体治疗（RLT），重点是一个晚期项目AlphaMedix™。靶向α疗法依赖于一个简单的概念：将生物载体靶向癌细胞的能力与发射α的放射性同位素的短程和高能细胞杀伤能力相结合。

The vector directs the radioisotope to the target cancer cells expressing the specific marker, even when they have spread throughout the body. This unique mechanism of action aims to damage or destroy target cancer cells, while limiting impact on nearby healthy cells. This novel precision medicine approach aims at changing the standard of care in some rare cancers to extend patients’ lives and improve their quality of life.

该载体将放射性同位素导向表达特定标记的靶癌细胞，即使它们已经扩散到全身。这种独特的作用机制旨在破坏或摧毁靶癌细胞，同时限制对附近健康细胞的影响。这种新颖的精准医学方法旨在改变一些罕见癌症的护理标准，以延长患者的生命并提高其生活质量。

Paul HudsonCEO, Sanofi“We are excited to partner with Orano in establishing a French pioneer that unites our respective expertise in biopharma and nuclear technology to drive groundbreaking progress in the fight agains.

赛诺菲首席执行官保罗·哈德森（PaulHudsonCEO）“我们很高兴能与奥拉诺（Orano）合作，建立一家法国先驱公司，将我们各自在生物制药和核技术方面的专业知识结合起来，推动对抗战取得突破性进展。